



TFW

<b>AMENDMENT TRANSMITTAL LETTER (Large Entity)</b>				Docket No. 0701.196A	
Applicant(s): Jerussi et al.					
Application No. 10/663,173	Filing Date September 16, 2003	Examiner Brian J. Davis	Customer No. 02264	Group Art Unit 1621	Confirmation No. 2834
Invention: <b>TREATMENT OF CNS DISORDERS WITH trans 4-(3,4- DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE</b>					
<b>COMMISSIONER FOR PATENTS:</b> <div style="float: right; border: 1px solid black; border-radius: 50%; padding: 10px; text-align: center;">             OIPE JAN 26 2006 PATENT &amp; TRADEMARK OFFICE           </div>					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	72 -	70 =	2	x \$50.00	\$100.00
INDEP. CLAIMS	11 -	14 =	0	x \$200.00	\$0.00
Multiple Dependent Claims (check if applicable) <input checked="" type="checkbox"/>					\$360.00
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$460.00</b>
<input type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input checked="" type="checkbox"/> A check in the amount of <b>\$460.00</b> to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 08-1935 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038.					
<b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>					
 Signature			Dated: January 24, 2006		
Edward Timmer, Esq. Registration No. 46,248 Heslin Rothenberg Farley & Mesiti P.C. 5 Columbia Circle Albany, New York 12203 Telephone (518) 452-5600 Facsimile (518) 452-5579			<div style="border: 1px solid black; padding: 5px;">         I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on          January 24, 2006          (Date)            Signature of Person Mailing Correspondence          Edward Timmer          Typed or Printed Name of Person Mailing Correspondence       </div>		
CC:					



Docket No: 0701.196A

*Jerussi et al.*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Applicant(s):</b>	Jerussi et al.	<b>Confirmation No.:</b>	2834
<b>Serial No.:</b>	10/663,173	<b>Group Art Unit:</b>	1621
<b>Filed:</b>	09/16/2003	<b>Examiner:</b>	Davis, Brian J.
<b>Docket No:</b>	0701.196A		
<b>Title:</b>	TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Mailing Date: January 24, 2006

**RESPONSE**

Dear Sir:

This is a Response to the Non-Final Office Action mailed on October 24, 2005. As the Action provided a three month period for response, a reply is due by January 24, 2006. Therefore, this Response is filed timely.

Claim amendments begin on page 2 of this paper.

Remarks begin on page 17 of this paper.

01/26/2006 YPOLITE1 00000082 10663173

01 FC:1202 100.00 OP  
02 FC:1203 360.00 OP